The FDA approval was based on results from the CABINET study, a phase 3 pivotal trial evaluating cabozantinib compared with placebo in two groups of patients with previously treated NETs: advanced pancreatic NETs and advanced extra-pancreatic NETs. The study was led by Jennifer Chan, MD, MPH, clinical director of the gastrointestinal cancer center and director of the program in carcinoid and neuroendocrine tumors at Dana-Farber Cancer Institute.

New research from Memorial Sloan Kettering Cancer Center (MSK) develops a new tool for studying mitochondrial DNA deletions; uncovers mechanisms of histiocytosis-associated neurodegeneration; and investigates how mutant stem cells co-opt regeneration to make tumors grow.

Researchers at City of Hope have found that cell mutations are necessary but not always sufficient for tumors to form. Instead, they suggest that additional risk factors that promote tumor growth, like chronic inflammation, are a key trigger for tumor formation. The study findings, published this month in Cancer Discovery, answer a question that scientists have long asked: Are cell mutations alone — whether genetically inherited or acquired through lifestyle choices — enough to cause cancer?

A critical analysis of the latest literature data on changes in the viability of cancer cells under the influence of terahertz radiation was reported.

POSTECH Develops Bio-conjugation Technology for Selective Protein Modification in Live Biological Systems.

Scientists have long struggled to target proteins that lack defined structure and are involved in cancer, neurodegenerative disorders like Parkinson’s disease, and other serious illnesses. Now, a new study from Scripps Research demonstrates a proof of concept for a new strategy: engineering proteases—enzymes that cut proteins at specific sites—to selectively degrade these elusive targets with high precision in the proteome of human cells.